China dairy giant Yili has registered record growth and increased market share in its recently-released H1FY2022 financial report, and has attributed this success to the sales of its value-added dairy products as well as its efforts in rapid new product...
This round-up looks at the latest financial report from major dietary supplement and infant formula firms, namely The a2 Milk Company, Blackmores, McPherson’s, Meiji, and BYHEALTH.
ASX-listed Australian firm McPherson’s has reported almost 90 per cent annual growth in its health business in FY22, with the herbals brand Fusion – previously owned by Blackmores’ Global Therapeutics – performing particularly well.
Blackmores will beef up its local inventory for the 13 markets that it currently operates in, design new pack sizes for markets such as Thailand, and target eye health growth in China over the next year, the company’s CEO told NutraIngredients-Asia.
China’s largest vitamin and dietary supplement (VDS) firm BYHEALTH is reaping the benefits of an expanding domestic market, as it reported yet another record year of profit and revenue growth.
Infant formula maker Bubs reported a record high gross revenue coming from corporate daigou companies, which help individual sellers navigate hurdles such as procurement and deliveries.
This round-up looks at the latest financial performance of nutraceutical and infant formula brands, including PERKii, The a2 Milk Company, Blackmores, Swisse's parent company H&H Group, and CBD specialist Elixinol.
BY-HEALTH’s revenue from online direct sales stores, such as Tmall, has increased six-fold in the first half of FY2021, and has already surpassed the total achieved in 2020.
